H Gallais
Overview
Explore the profile of H Gallais including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montana M, Chochoi N, Monges P, Ravaux I, Faraut F, Gensollen S, et al.
Pathol Biol (Paris)
. 2004 Mar;
52(2):66-75.
PMID: 15001234
Treatment of visceral leishmaniasis in HIV patients encounters inefficacy and relapse due to drug resistance, toxicity and immunodepression. Our goal was to evaluate treatment of these patients by liposomal amphotericin...
2.
Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut J, et al.
J Clin Microbiol
. 2004 Feb;
42(2):570-7.
PMID: 14766818
The susceptibility of human immunodeficiency virus type 2 (HIV-2) to protease inhibitors (PI) is largely unknown. We studied HIV-2 protease genes from 21 HIV-2-infected patients who were exposed or not...
3.
Bouhnik A, Moatti J, Vlahov D, Gallais H, Dellamonica P, Obadia Y
J Epidemiol Community Health
. 2002 Apr;
56(5):349-53.
PMID: 11964431
Study Objective: This study examined the impact of highly active antiretroviral therapies (HAART) on sexual risk behaviours of HIV infected injecting drug users (IDUs) included in the French MANIF 2000...
4.
Spadari M, Tissot-Dupont H, Tichadou L, Arditti J, Jouglard J, David J, et al.
Therapie
. 2001 Jul;
56(2):191-3.
PMID: 11471375
No abstract available.
5.
Tissot-Dupont H, Obadia Y, Gallais H, Mege J, Capo C
Clin Diagn Lab Immunol
. 2000 Sep;
7(5):832-4.
PMID: 10973464
The circulating levels of immune activation markers, including neopterin, tumor necrosis factor receptor type II, and interleukin-2 receptors, are increased in human immunodeficiency virus-infected patients. We show here that highly...
6.
Fournier P, Tissot-Dupont H, Gallais H, Raoult D
Emerg Infect Dis
. 2000 May;
6(3):290-2.
PMID: 10827119
We report a second case of laboratory-confirmed infection caused by Rickettsia mongolotimonae in Marseille, France. This rickettsiosis may represent a new clinical entity; moreover, its geographic distribution may be broader...
7.
Carrieri M, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, et al.
Drug Alcohol Depend
. 2000 May;
60(1):51-4.
PMID: 10821989
Some HIV-infected injecting drug users (IDUs) on drug abuse maintenance treatment have access to highly active antiretroviral therapy (HAART); this raises questions about the effects of individual treatments on the...
8.
Tamalet C, Pasquier C, Yahi N, Colson P, Poizot-Martin I, Lepeu G, et al.
J Med Virol
. 2000 May;
61(2):181-6.
PMID: 10797372
Baseline genotype resistance analysis was carried out in 48 adults with primary HIV-1 infection between 1995 and 1998 before starting early combination therapy. Seventeen percent (8/48) of the isolates displayed...
9.
Tissot-Dupont H, Capo C, Brunet C, Dignat-George F, Obadia Y, Gallais H, et al.
Clin Exp Immunol
. 2000 Apr;
120(1):107-12.
PMID: 10759771
HIV infection is associated with cytokine production by monocytes and expansion of a monocyte subset that expresses high levels of CD16. Our study was designed to investigate the effects of...
10.
Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, et al.
J Clin Microbiol
. 1999 Nov;
37(12):4099-106.
PMID: 10565938
The aim of the present study was to evaluate the resistance-associated mutations in 302 human immunodeficiency virus type 1 (HIV-1)-infected patients receiving combination therapy and monitored in Marseille, France, hospitals...